PP
CRSP icon

Paladin Partners’s CRISPR Therapeutics CRSP Stock Holding History

Paladin Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.18K Buy
+150
New +$7.91K 0.01% 138

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Paladin Partners's CRSP Position: Q2 2026 in Review

Paladin Partners opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 150 shares worth $8.18K. The stake represents 0.01% of the portfolio and ranks #138 among its holdings.

521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Paladin Partners held 150 shares of CRISPR Therapeutics worth $8.18K as of Q2 2026.
  • CRISPR Therapeutics was a new Paladin Partners position in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of Paladin Partners's portfolio in Q2 2026, its #138 holding.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Paladin Partners's 13F filing for Q2 2026, filed 7 Aug 2026.